Am Fam Physician. 2004 Dec 1;70(11):2109.
Calcium and Prevention of Colorectal Cancer
Do calcium supplements prevent colorectal cancer and adenomatous polyps?
Combined evidence from two clinical trials of calcium supplementation lasting for several years revealed a reduced rate of recurrent colorectal adenoma. However, evidence is insufficient to recommend supplementation with dietary calcium for patients who have never had an adenoma.
A recent review1 of epidemiologic evidence did not show that calcium supplementation prevents colon cancer. However, epidemiologic studies of dietary interventions for cancer prevention are vulnerable to survivor bias, confounding factors,and inaccurate dietary recall.
Weingarten and colleagues reviewed the literature to find randomized controlled trials (RCTs) of calcium supplementation used for prevention of colon cancer. Such studies are difficult because they require a large number of patients for a long time. Weingarten found two studies that included a total of 1,346 patients with a previous diagnosis of colon adenoma. In one study, patients took 1,200 mg of calcium daily for four years. Patients in the other study took 2,000 mg per day for three years. When data from the studies were combined, there was a 26 percent relative reduction in recurrent adenomas (odds ratio, 0.74; 95 percent confidence interval, 0.58 to 0.95). However, there were not enough new diagnoses of colon cancer to support conclusions about calcium supplementation’s effect on cancer prevention. No RCTs were found that studied calcium supplementation for primary cancer prevention in patients who had never had a polyp or tumor.
Dietary calcium supplementation promises to reduce the risk of colon cancer moderately. Although it would be appealing to find a simple, inexpensive, and safe dietary supplement to prevent colon cancer, comprehensive programs for healthy living are more likely to be effective. For prevention of colon cancer, the American Cancer Society recommends increasing the intensity and duration of physical activity; eating more vegetables and fruits; limiting intake of red meat; avoiding obesity; and avoiding excess alcohol consumption.2
CLARISSA KRIPKE, M.D.
Weingarten MA, et al. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst Rev. 2004;(3):CD003548.
1. Martinez ME, Willett WC. Calcium, vitamin D, and colorectal cancer: a review of the epidemiologic evidence. Cancer Epidemiol Biomarkers Prev. 1998;7:163–8.
2. Byers T, Nestle M, McTiernan A, Doyle C, Currie-Williams A, Gansler T, et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2002;52:92–119.
Link Between Metformin and Lactic Acidosis?
Does metformin cause lactic acidosis?
There is no evidence that metformin causes lactic acidosis, even in patients with renal insufficiency or other comorbidities. Although caution is still indicated in patients with multiple or severe comorbidities, it appears that the initial concern about lactic acidosis with this drug was misplaced.
Unlike other agents used in the treatment of type 2 diabetes mellitus, metformin has been shown to reduce mortality in obese patients.1 It is therefore being used increasingly often for the treatment of type 2 diabetes. However, many physicians are concerned about a possible increase in the risk of lactic acidosis, particularly in patients who have cardiovascular disease, renal disease, liver problems, chronic respiratory disease, or advanced age. Phenformin, another biguanide, was withdrawn from the market after a rate of 40 to 64 cases of lactic acidosis per 100,000 patient-years was reported.
Salpeter and colleagues found 176 studies that met their inclusion criteria, of which 118 were prospective clinical trials. The 176 studies followed 26,099 patients who took metformin for a total of 65,621 patient-years, and 8,943 control patients who did not take metformin for 30,002 patient-years.
Although many studies excluded patients with comorbidities, a significant number did not. For example, 81 did not exclude patients with renal insufficiency. Remarkably, there was not a single case of fatal or nonfatal lactic acidosis in any of the patients, whether or not they took metformin. Therefore, the upper limit of a 95 percent confidence interval with zero at the lower end is 8.4 cases per 100,000 patient-years in patients taking metformin and 9.0 cases per 100,000 patient-years in patients not taking it. There was no difference in intermediate physiologic outcomes, such as change in lactate levels, and no evidence of publication bias. The authors cite data showing that contraindications to the use of metformin are largely ignored in clinical practice. It appears that, in this case, physicians are correct.
MARK EBELL, M.D., M.S.
Salpeter S, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2004;(3):CD002967.
1. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [published correction appears in Lancet 1998;352:1557] Lancet. 1998;352:854–65.
Copyright © 2004 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Access the latest issue of American Family Physician